Leerink downgraded Regulus (RGLS) to Market Perform from Outperform with a $7 price target after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS: